Stocks of the Hour: Iceni Gold, Avita Medical, Antisense Therapeutics
Stocks of the Hour: Iceni Gold, Avita Medical, Antisense Therapeutics
Iceni Gold (ASX:ICL) has hit a high-grade vein at the Everleigh well in Western Australia. Technical Director David Nixon comments: "The high-grade rock chip results from the vein are supported by the underlying UFF+ soil anomaly, prospectivity indicators and the multiple coincident targets." Shares are trading 53.13 per cent higher at 9.8 cents.
Iceni Gold（澳大利亞證券交易所股票代碼：ICL）在西澳大利亞州的Everleigh油井遇到了高等級礦脈。技術總監戴維·尼克松評論說：“來自礦脈的高品質岩屑結果得到了潛在的UFF+土壤異常、前景指標和多個重合目標的支持。”股價上漲53.13％，至9.8美分。
Avita Medical (ASX:AVH) has announced FDA Approval of its spray-on skin cell product RECELL for the treatment of full thickness skin defects. CEO Jim Corbett comments, "The FDA approval now offers surgeons a best-in-class treatment option for a multitude of severe wounds within inpatient and outpatient settings." Shares are trading 14.22 per cent higher at $4.90.
Avita Medical（ASX: AVH）宣佈美國食品藥品管理局批准其用於治療全層皮膚缺陷的噴霧式皮膚細胞產品RECELL。首席執行官吉姆·科貝特評論說：“美國食品藥品管理局的批准現在爲外科醫生提供了治療住院和門診環境中多種嚴重傷口的最佳治療選擇。”股價上漲14.22％，至4.90美元。
Antisense Therapeutics (ASX:ANP, US OTC:ATHJY, FSE:AWY) has announced that the first patient has been dosed in the company's Phase IIb Duchenne Muscular Dystrophy Trial. Three patients are currently in the screening phase of the trial. Shares are trading 6.35 per cent higher at 6.7 cents.
Antisense Therapeutics（澳大利亞證券交易所代碼：ANP，美國場外交易代碼：ATHJY，FSE: AWY）宣佈，該公司的IIb期杜興氏肌肉萎縮症試驗已對首位患者進行了給藥。目前有三名患者處於試驗的篩查階段。股價上漲6.35％，至6.7美分。
